Matthew S Davids MD MMSc

Hematologic Oncology

Associate Professor of Medicine, Harvard Medical School, Director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute

Join to view full profile

450 Brookline AveBoston, MA 02215
Phone+1 617-632-3000
Fax+1 617-632-5822

Dr. Davids is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Davids' full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2008
Yale School of MedicineClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2022 - 2026
MA State Medical License 2008 - 2026
NY State Medical License 2007 - 2009
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017

Clinical Trials

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Start of enrollment: 2013 May 16
COMPLETED
PHASE1
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL Start of enrollment: 2014 Jun 27
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
ACTIVE_NOT_RECRUITING
PHASE2

Publications & Presentations

PubMed

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Jennifer L Crombie, Austin I Kim, Robert Redd, Nancy Bartlett, Victoria Patterson
Clinical Lymphoma, Myeloma & Leukemia. 2026-08-01
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocy...
Matthew S Davids, Toby A Eyre, Jennifer A Woyach, Lindsey E Roeker, Alessandra Ferrajoli
Lancet. 2026-08-01
Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death.
Fen Zhu, Jing Wang, Christine E Ryan, Liam Hackett, Jeremy Zhang
Blood Neoplasia. 2026-08-01

Journal Articles

The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL
Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study
Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other

The Rise of Apoptosis: Targeting Apoptosis in Hematologic Malignancies
Matthew Davids, MD, Blood
https://www.doximity.com/articles/98c8dcba-e43a-4f7a-a7f7-4f3bd29ea5d9
UpToDate, Wolters Kluwer Health - 2013-03-29

Press Mentions

Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLLJanuary 8th, 2026
ICML 2025: Progress and Future Directions in CLL TreatmentJuly 7th, 2025
Integrating Real-World Evidence and Clinical Trial Data in CLL ManagementJanuary 17th, 2025